

# Yuichi Saito

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8891926/publications.pdf>

Version: 2024-02-01

72  
papers

909  
citations

567281

15  
h-index

552781

26  
g-index

73  
all docs

73  
docs citations

73  
times ranked

587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Uric acid and cardiovascular disease: A clinical review. <i>Journal of Cardiology</i> , 2021, 78, 51-57.	1.9	124
2	Clinical expert consensus document on standards for measurements and assessment of intravascular ultrasound from the Japanese Association of Cardiovascular Intervention and Therapeutics. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 1-12.	2.3	83
3	Clinical expert consensus document on intravascular ultrasound from the Japanese Association of Cardiovascular Intervention and Therapeutics (2021). <i>Cardiovascular Intervention and Therapeutics</i> , 2022, 37, 40-51.	2.3	43
4	Contemporary coronary drug-eluting and coated stents: a mini-review. <i>Cardiovascular Intervention and Therapeutics</i> , 2021, 36, 20-22.	2.3	41
5	Relation between severity of myocardial bridge and vasospasm. <i>International Journal of Cardiology</i> , 2017, 248, 34-38.	1.7	39
6	Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 19-29.	2.3	37
7	Relation of Lipid Content of Coronary Plaque to Level of Serum Uric Acid. <i>American Journal of Cardiology</i> , 2015, 116, 1346-1350.	1.6	36
8	Percutaneous coronary intervention strategies in patients with acute myocardial infarction and multivessel disease: Completeness, timing, lesion assessment, and patient status. <i>Journal of Cardiology</i> , 2019, 74, 95-101.	1.9	25
9	Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. <i>Internal Medicine</i> , 2020, 59, 311-321.	0.7	25
10	Safety and usefulness of acetylcholine provocation test in patients with no culprit lesions on emergency coronary angiography. <i>International Journal of Cardiology</i> , 2018, 269, 27-30.	1.7	22
11	Relation of Elevated Serum Uric Acid Level to Endothelial Dysfunction in Patients with Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 362-367.	2.0	20
12	Intracoronary Acetylcholine Provocation Testing—Omission of the 20- $\mu$ g Dose Is Feasible in Patients Without Coronary Artery Spasm in the Other Coronary Artery. <i>Circulation Journal</i> , 2016, 80, 1820-1823.	1.6	18
13	Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2020, 5, 92.	6.1	18
14	Validation of the ABCD-GENE score to identify high platelet reactivity in east Asian patients undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2021, 327, 15-18.	1.7	18
15	Decreased resting coronary flow and impaired endothelial function in patients with vasospastic angina. <i>Coronary Artery Disease</i> , 2019, 30, 291-296.	0.7	16
16	Impact of CADILLAC and GRACE risk scores on short- and long-term clinical outcomes in patients with acute myocardial infarction. <i>Journal of Cardiology</i> , 2021, 78, 201-205.	1.9	15
17	2-Year Clinical Outcomes of anÅAbluminal GrooveÅA Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1679-1687.	2.9	14
18	Impact of PARIS and CREDO-Kyoto Thrombotic and Bleeding Risk Scores on Clinical Outcomes in Patients With Acute Myocardial Infarction. <i>Circulation Journal</i> , 2022, 86, 622-629.	1.6	14

#	ARTICLE	IF	CITATIONS
19	Clinical Characteristics and Prognosis of Patients With No Standard Modifiable Risk Factors in Acute Myocardial Infarction. <i>Heart Lung and Circulation</i> , 2022, 31, 1228-1233.	0.4	14
20	Prognostic Impact of Branch Vessel Involvement on Computed Tomography versus Clinical Presentation of Malperfusion in Patients With Type a Acute Aortic Dissection. <i>American Journal of Cardiology</i> , 2021, 152, 158-163.	1.6	13
21	Impact of Active and Historical Cancer on Short- and Long-Term Outcomes in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, 159, 59-64.	1.6	13
22	Treatment strategies and in-hospital mortality in patients with type A acute aortic dissection and coronary artery involvement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2024, 167, 596-601.e3.	0.8	13
23	Invasive assessment of microvascular function in patients with valvular heart disease. <i>Coronary Artery Disease</i> , 2018, 29, 223-229.	0.7	12
24	Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2019, 73, 1-6.	1.9	12
25	Paroxysmal atrial fibrillation during intracoronary acetylcholine provocation test. <i>Heart and Vessels</i> , 2017, 32, 902-908.	1.2	11
26	Night-time blood pressure variability negatively correlated with reactive hyperemia index. <i>International Journal of Cardiology</i> , 2017, 230, 332-334.	1.7	9
27	Preoperative Assessment of Endothelial Function for Prediction of Adverse Events After Cardiovascular Surgery. <i>Circulation Journal</i> , 2018, 82, 118-122.	1.6	9
28	Relation of Plasma Xanthine Oxidoreductase Activity to Coronary Lipid Core Plaques Assessed by Near-Infrared Spectroscopy Intravascular Ultrasound in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 125, 1006-1012.	1.6	9
29	Feasibility and safety of outpatient cardiac catheterization with intracoronary acetylcholine provocation test. <i>Heart and Vessels</i> , 2018, 33, 846-852.	1.2	8
30	Triple, dual, and single antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 44-51.	2.3	8
31	Volume-Outcome Relationships for Percutaneous Coronary Intervention in Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2022, 11, e023805.	3.7	8
32	Validation of the Domestic High Bleeding Risk Criteria for Japanese Patients with Acute Myocardial Infarction. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 299-309.	2.0	8
33	Impact of Elevated Serum Uric Acid Level on Target Lesion Revascularization After Percutaneous Coronary Intervention for Chronic Total Occlusion. <i>American Journal of Cardiology</i> , 2019, 124, 1827-1832.	1.6	7
34	Novel predictors of late lumen enlargement in distal reference segments after successful recanalization of coronary chronic total occlusion. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 546-552.	1.7	7
35	Increased platelet inhibition after switching from prasugrel to low-dose ticagrelor in Japanese patients with prior myocardial infarction. <i>Journal of Cardiology</i> , 2020, 75, 473-477.	1.9	7
36	Greater coronary lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound in patients with elevated xanthine oxidoreductase: a mechanistic insight. <i>Heart and Vessels</i> , 2021, 36, 597-604.	1.2	7

#	ARTICLE	IF	CITATIONS
37	In-hospital adverse events in low-risk patients with acute myocardial infarction – Potential implications for earlier discharge. <i>Journal of Cardiology</i> , 2022, 79, 747-751.	1.9	7
38	Resistive reserve ratio and microvascular resistance reserve in patients with coronary vasospastic angina. <i>Heart and Vessels</i> , 2022, 37, 1489-1495.	1.2	7
39	Feasibility of omitting provocation test with 50µg of acetylcholine in left coronary artery. <i>Heart and Vessels</i> , 2017, 32, 685-689.	1.2	6
40	Impact of tissue protrusion after coronary stenting in patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 401-407.	1.5	6
41	Long-term serial functional evaluation after implantation of the Fantom sirolimus-eluting bioresorbable coronary scaffold. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 431-436.	1.7	6
42	Gender differences in factors associated with vasospastic angina. <i>International Journal of Cardiology</i> , 2022, 349, 7-11.	1.7	6
43	Diagnostic accuracy of intraluminal blood speckle intensity on intravascular ultrasound for physiological assessment of coronary artery stenosis. <i>Coronary Artery Disease</i> , 2017, 28, 145-150.	0.7	5
44	Systemic endothelial dysfunction in patients with vasospastic and microvascular angina: serum uric acid as a marker of reactive hyperemia index. <i>Coronary Artery Disease</i> , 2020, 31, 565-566.	0.7	5
45	Academic Research Consortium Definition of High Bleeding Risk in Clinical Practice – Validation and Beyond. <i>Circulation Journal</i> , 2021, 85, 806-807.	1.6	5
46	Impact of glycemic variability on coronary and peripheral endothelial dysfunction in patients with coronary artery disease. <i>Journal of Cardiology</i> , 2022, 79, 65-70.	1.9	5
47	Factors associated with discordance between fractional flow reserve and resting full-cycle ratio. <i>Journal of Cardiology</i> , 2022, 80, 9-13.	1.9	5
48	Intraluminal Intensity of Blood Speckle on Intravascular Ultrasound, a Novel Predictor of Periprocedural Myocardial Injury After Coronary Stenting. <i>American Journal of Cardiology</i> , 2017, 120, 1084-1089.	1.6	4
49	Preoperative endothelial function and long-term cardiovascular events in patients undergoing cardiovascular surgery. <i>Heart and Vessels</i> , 2019, 34, 318-323.	1.2	4
50	Vasospastic angina and overlapping cardiac disorders in patients resuscitated from cardiac arrest. <i>Heart and Vessels</i> , 2021, 36, 321-329.	1.2	4
51	Abluminal groove-filled biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent: three-year results of the TARGET All Comers trial. <i>EuroIntervention</i> , 2021, 17, e332-e334.	3.2	4
52	Relation Between Cancer and Vasospastic Angina. <i>Advances in Therapy</i> , 2021, 38, 4344-4353.	2.9	4
53	Feasibility of management of hemodynamically stable patients with acute myocardial infarction following primary percutaneous coronary intervention in the general ward settings. <i>PLoS ONE</i> , 2020, 15, e0240364.	2.5	4
54	Relation of glucose variability to vulnerable plaque formation in patients with coronary artery disease. <i>Heart and Vessels</i> , 2022, , 1.	1.2	4

#	ARTICLE	IF	CITATIONS
55	Predictive value of coronary artery dilation response to nitrate for a positive intracoronary acetylcholine provocation test. <i>Coronary Artery Disease</i> , 2016, 27, 551-555.	0.7	3
56	Novel predictor of target vessel revascularization after coronary stent implantation: Intraluminal intensity of blood speckle on intravascular ultrasound. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 604-610.	1.7	3
57	Clinical outcomes of complex lesions treated with an abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1023-1028.	1.7	3
58	Decreased Double Product at Rest in Patients With Severe Vasospasm. <i>Heart Lung and Circulation</i> , 2020, 29, 1511-1516.	0.4	3
59	Mental Health Status in Patients Undergoing Intracoronary Acetylcholine Provocation Test. <i>Advances in Therapy</i> , 2020, 37, 3807-3815.	2.9	3
60	The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. <i>Cardiology in Review</i> , 2020, 28, 208-212.	1.4	3
61	Impact of clinical presentations on lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1151-1158.	1.5	3
62	Trajectory of renal function change and kidney injury after percutaneous coronary intervention in patients with stable coronary artery disease. <i>Heart and Vessels</i> , 2021, 36, 315-320.	1.2	3
63	Impact of Serum Uric Acid Level on Systemic Endothelial Dysfunction in Patients with a Broad Spectrum of Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4530.	2.4	3
64	Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1031-1039.	2.0	3
65	Derivation of a Novel Scoring System Predicting High Platelet Reactivity on Prasugrel in Patients with Coronary Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1625-1633.	2.0	3
66	Differential impact of abluminal <sc>groove-filled biodegradable polymer sirolimus-eluting</sc> stent versus <sc>durable polymer everolimus-eluting</sc> stent on and off dual antiplatelet therapy. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 357-365.	1.7	1
67	Impact of perioperative antithrombotic strategies on clinical events in non-cardiac surgery. <i>Heart and Vessels</i> , 2022, , 1.	1.2	1
68	Cerebral Embolic Protection. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 869-871.	2.9	0
69	Impact of myocardial bridge on late lumen enlargement in distal reference segments after recanalization of coronary chronic total occlusion. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 775-782.	1.5	0
70	IVUS Tells a Potential of Late Lumen Enlargement After CTO PCI: The Story so Far. <i>Cardiovascular Revascularization Medicine</i> , 2021, 25, 18-19.	0.8	0
71	Predictivity of acute kidney injury risk scores for late kidney injury in patients with chronic coronary syndrome. <i>Heart and Vessels</i> , 0, , .	1.2	0
72	Impact of myocardial bridge on non-culprit vessel lumen changes in patients with acute coronary syndrome. <i>Heart and Vessels</i> , 0, , .	1.2	0